Capricor Therapeutics, Inc. (NASDAQ:CAPR) Q1 2022 Earnings Conference Call May 10, 2022 4:30 PM ET

Company Participants

Anthony Bergmann - CFO & Corporate Treasurer

Linda Marban - Co-Founder, President, CEO & Director

Conference Call Participants

Joseph Pantginis - H.C. Wainwright & Co.

Operator

Good day, ladies and gentlemen, and welcome to the Capricor Therapeutics, Inc. First Quarter 2022 Financial Earnings Call. [Operator Instructions]. At this time, I would like to turn the call over to Mr. Bergmann, Capricor Therapeutics' Chief Financial Officer. Please go ahead, sir.

Anthony Bergmann

Thank you. Thank you for joining today's call. Before we start, I would like to state that we will be making certain forward-looking statements during today's presentation. These statements may include statements regarding, among other things, the efficacy, safety and intended utilization of our product candidates, our future research and development plans, including our anticipated conduct and timing of preclinical and clinical studies; our plans to present or report additional data; our plans regarding regulatory filings, potential regulatory developments involving our product candidates, potential milestone payments; and our possible uses of existing cash and investment resources.

These forward-looking statements are based on current information, assumptions and expectations that are subject to change and involve a number of risks and uncertainties that may cause actual results to differ materially from those contained in the forward-looking statements. These and other risks are described in our periodic filings made with the SEC, including our quarterly and annual reports. You are cautioned not to place undue reliance on these forward-looking statements, and we disclaim any obligation to update such statements.

And with that, I'll turn the call over to Linda Marban, CEO.

Linda Marban

Good afternoon, and thank you for joining us for our first quarter 2022 conference call. Today, I will provide updates on our lead product, CAP-1002, and as well as our exosomes platform technology. We have made significant progress this quarter, highlighted first and foremost, by securing a commercial partnership with Nippon Shinyaku for our Duchenne muscular dystrophy program, bringing in $30 million in upfront cash to fund our Phase III program.

Further, we saw the publication of our Phase II HOPE-2 result in The Lancet, one of the most prestigious medical journals in the world. If you haven't read this publication, I encourage you to please do so as it will strengthen your understanding of the positive results demonstrated in the Phase II HOPE-2 trial of CAP-1002. The paper speaks to both the scientific and clinical rationale for our Phase III HOPE-3 clinical trial that I shall discuss in greater detail in a few minutes.